Inflation Reduction Act
-
Caught my eye — 3/22/24
Read more: Caught my eye — 3/22/24If you’re one of those people who is working from the couch today, I salute you. It really is the most fun day of sports. I was mocked for the way I picked my bracket (where wouId I rather live?) but I had a clean bracket until Kentucky. I blame my newfound like of bourbon.…
-
Caught my eye — 3/8/24
Read more: Caught my eye — 3/8/24Happy International Women’s Day. Best display of International Women’s day I’ve ever seen was in Russia when I was studying abroad. They took it SERIOUSLY. Not just a LinkedIn Holiday. Cat-astrophe? No, just a political speech – not reality. President Biden talked about increasing the number of negotiated drugs up to 50 a year. Not…
-
Caught my eye, Copay Accumulators, Inflation Reduction Act, Medicare Part D, Pharmacy Benefit ManagersCaught my eye — 3/1/24
Read more: Caught my eye — 3/1/24It took my until 5 pm on Thursday to figure out why there was a frog on the Microsoft tool bar. Leap year. Frog. Leap. Sigh. I prefer not. Congress seems to have hit the pause button (at least temporarily) on pharmacy benefit manager (PBM) reform. And that sort of felt okay because, realistically, things…
-
Caught my eye — 2/23/24
Read more: Caught my eye — 2/23/24Gross to Net, a Saga. As soon as I saw Adam Fein’s Drug Channels article on Gross to Net in Part D redesign, I knew it would throw off my day. It was just catchy enough to cause a buzz and get the attention of Heads of Market Access at pharmaceutical companies and start the…
-
Save the date: 4 for 1, IRA Arguments
Read more: Save the date: 4 for 1, IRA ArgumentsOn March 7 the District Court of New Jersey will hear oral arguments from 4 pharmaceutical companies against the Inflation Reduction Act (IRA) in one day – BMS, Janssen, Novartis and Novo Nordisk. When the arguments line up and time is ticking, get it done. All four companies have drugs that are part of the…
-
Yays and Nays
Read more: Yays and NaysThis afternoon I’m giving a talk to a group of patient advocates on the Medicare prescription drug benefit (Part D). As I prepared, I was struck by the fact that this is one of the few times that I feel that I’m (mostly) giving out good policy news. Are there downsides to the Medicare Part…
-
Caught my eye, CMMI, Drug Prices, Inflation Reduction Act, Insulin, Medicare Negotiation, State-based ReformCaught my eye — 2/2/24
Read more: Caught my eye — 2/2/24It is a dumb bucket list thing but one day I will go experience the Groundhog Day festivities. Dream big, I know. Cell and Gene Update. This week the Centers for Medicare and Medicaid Innovation (CMMI) released the Cell and Gene Therapy (CGT) Access model which will initially focus on sickle cell disease. It is…
-
Caught my eye — 1/19/23
Read more: Caught my eye — 1/19/23A thoughtful piece on price hikes. Price hikes are the routine story of January. Look price hikes! But because net price hides behind discounts and rebates, the full story is seldom in media. Here is a story that is (finally) a little more balanced on price hikes (and decreases). It even talks about the new…
-
Caught my eye — 1/12/24
Read more: Caught my eye — 1/12/24Aye-n’t going to happen. Last week I covered how Florida had their importation plan approved by the Food and Drug Administration. It all seems so unlikely to happen or, if it does, it has a lot to go through before it happens. And already the Canadians are saying no thank you. International Math. The Commonwealth…
-
Word of the Year: Tangled
Read more: Word of the Year: TangledGive me time off and I’m likely to find myself in over my head with a project of my own making. #cantstopwontstop. Like deciding to bake 120 giant cookies and then deciding that I didn’t like the look of half of them and starting over. Health policy took a backseat to cookies and scones for…
Latest news
- Caught my eye — 1/24/25
- Caught my eye — 1/16/25
- Caught my eye — 1/10/25
- Caught my eye — 12/20/24
- Nurturing the Potential of Biosimilars
Categories
- 340B (31)
- Affordable Care Act (3)
- Alzheimer's (4)
- Biosimilars (19)
- Caught my eye (53)
- Chevron Deference (2)
- CMMI (8)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (28)
- Drug shortages (7)
- DTC (2)
- Employers (7)
- Generics (4)
- Health Equity (3)
- Healthcare Costs (24)
- ICER (7)
- Importation (2)
- Inflation Reduction Act (42)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (3)
- Medicare Advantage (13)
- Medicare Negotiation (44)
- Medicare Part D (40)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (6)
- Obesity (18)
- On the Horizon (1)
- Orphan Drugs (2)
- Pharmacy Benefit Managers (25)
- Reference Pricing (4)
- State-based Reform (13)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (2)
- Value (8)